MAP2K1 and neurofibromatosis type 1: The EGFR MEK1/2 inhibitor combination is further supported by findings in treatment refractory PDAC patients who subsequently received combination erlotinib and selumetinib, a MEK1/2 inhibitor that recently received an orphan drug designation for neurofibromatosis type 1 [44].